Tirzepatide + Semaglutide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Jul 30, 2019 → Feb 15, 2021
NCT ID
NCT03987919About Tirzepatide + Semaglutide
Tirzepatide + Semaglutide is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT03987919. Target conditions include Type 2 Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06354101 | Pre-clinical | Withdrawn |
| NCT05822830 | Phase 3 | Completed |
| NCT03987919 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes